No se publicó un resumen junto con este documento; las guías de sociedades, las vías de consenso y las declaraciones científicas suelen difundirse sin él. Consulte los Puntos Clave y el PDF enlazado para ver el contenido completo.
“We developed a standardized vocabulary for documenting and reporting critical cardiovascular adverse events, along with specifications for the exchange of that information between computer systems. The key use will be in reporting findings to the FDA, whether in the context of clinical trials, pharmacovigilance, or device surveillance. Ultimately, we anticipate widespread adoption of this vocabulary throughout healthcare (including routine clinical care) as a catalyst for accelerating improvements in patient management and treatment.”
Hicks et al. (Mon,) studied this question.